Belching is a common bodily function, but when it escalates to a level that interferes with daily life, it is defined as belching disorders. International surveys have reported that approximately 1% of adults have belching disorders, but the percentage in Japan and the factors involved often elude medical professionals.

To examine the relationship between the rate of belching disorders, comorbidities, and lifestyles in Japan, a research team led by Professor Yasuhiro Fujiwara of Osaka Metropolitan University’s Graduate School of Medicine conducted a web survey of 10,000 adults. The results showed that 1.5%, or 151 people, had belching disorders. This was more prevalent in those who were men, drank alcohol, and were taking acid reflux medications.

Additionally, it was found that the presence of gastrointestinal disease, eating until feeling full, and extremely low or high chewing frequency were significantly associated with the development of belching disorders. Conversely, a high consumption of carbonated beverages had no association.

“The problem with belching disorders is that they take a long time to treat and are only practiced in a limited number of medical facilities,” stated Professor Fujiwara. “In the future, the evaluation of the number of times someone chews and the effects of improved dietary habits in patients with belching disorders will provide a treatment option for patients to perform on their own.”



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *

Before you post, please prove you are sentient.

What is 7 multiplied by 8?

Explore More

Colon cancer: Dying cancer cells give neighboring tumor cells instructions on how to survive

Colorectal carcinoma is the second most common cause of cancer death in Germany. Although cancer research in recent years has been able to significantly improve early diagnosis and therapy, the

Incurable liver disease may prove curable

Research led by Associate Professor Duc Dong, Ph.D., has shown for the first time that the effects of Alagille syndrome, an incurable genetic disorder that affects the liver, could be

HIV drug stabilizes disease progression in metastatic colorectal cancer

New clinical research shows that lamivudine, a reverse transcriptase inhibitor widely used in HIV therapy, stopped disease progression in 25% of patients with fourth-line metastatic colorectal cancer. Findings from the